These findings are further supported by real-world data from the Mount Sinai chronic kidney disease registry and the Geisinger Health System cohort that assessed the risk of AKI associated with the use of SGLT-2 inhibitors compared to use of non-SGLT-2 inhibitor antihyperglycemic agents using propensity-score matched analyses [13]. Here, SLC5A2 is linked to acute kidney injury.